What Is Oxiracetam?

Oxiracetam is a synthetic racetam nootropic that is 3 to 5 times more potent than piracetam by weight. Developed in the 1970s, it is notable for its mild stimulatory properties, which distinguish it from the more subtle cognitive effects of piracetam. Oxiracetam is prescribed in Italy (as Neuromet) and some other European countries for cognitive impairment.

How Oxiracetam Works

Oxiracetam modulates AMPA receptors and enhances cholinergic neurotransmission, similar to piracetam. Additionally, it increases D-aspartate release in the hippocampus, which supports NMDA receptor activation and long-term potentiation (LTP), the cellular mechanism underlying memory formation. This glutamatergic enhancement likely explains its mild stimulatory effect, which users describe as increased mental energy without the jitteriness of caffeine.

Oxiracetam Dosage

Standard research dose: 800 to 2,400 mg per day, divided into 2 to 3 doses. Water-soluble, can be taken with or without food. Choline co-supplementation recommended. Half-life: 8 to 10 hours.

Clinical Evidence

A 1997 study in Psychopharmacology found oxiracetam improved logical performance and attention in healthy volunteers. Italian clinical trials in elderly patients with dementia showed improvements in memory and cognitive function scores. A comparative study found oxiracetam superior to piracetam for certain logical reasoning tasks. However, the overall clinical evidence base is smaller than piracetam, with fewer large-scale RCTs.

Oxiracetam vs Piracetam: How They Compare

Oxiracetam and piracetam are both water-soluble racetams with similar core mechanisms (AMPA modulation, cholinergic enhancement). Oxiracetam adds mild stimulatory properties through D-aspartate and NMDA receptor effects, making it better suited for tasks requiring sustained focus and logical reasoning. Piracetam has the larger evidence base, longer track record, and broader cognitive profile (verbal fluency, memory, cerebral blood flow). For researchers wanting the foundational racetam with the most clinical data, piracetam is the starting point.

Legal Status in Canada

Oxiracetam is not a controlled substance in Canada. It is not scheduled under the CDSA and is available for research purposes.

Related Resources

• Piracetam Dosage Guide
• Piracetam Side Effects
• Buy Piracetam in Canada
• The Complete Guide to Racetam Nootropics

What Is CDP-Choline (Citicoline)?

CDP-Choline (cytidine 5′-diphosphocholine), also known as citicoline, is an endogenous compound that serves as an intermediate in the synthesis of phosphatidylcholine, a major component of neuronal cell membranes. It provides both choline and cytidine (which converts to uridine), offering dual neuroprotective and cognitive benefits.

How CDP-Choline (Citicoline) Works

CDP-Choline is hydrolyzed to choline and cytidine in the gut. Choline supports acetylcholine synthesis (critical when stacking with racetams). Cytidine converts to uridine, which supports RNA synthesis and synaptic membrane repair through the Kennedy pathway. This dual mechanism makes CDP-Choline both a choline source and a neuroprotective compound. Studies show it also increases dopamine receptor density in the striatum.

CDP-Choline (Citicoline) Dosage

Standard dose: 250 to 500 mg per day. When pairing with piracetam, 250 mg CDP-Choline per 1,200 mg piracetam is a common ratio. Clinical trials for stroke recovery used 500 to 2,000 mg/day. Take with or without food.

Clinical Evidence

CDP-Choline has a strong evidence base. A 2005 Cochrane review of 14 trials (1,336 patients) found that citicoline had a positive effect on memory and behaviour in patients with cognitive deficits associated with cerebrovascular disorders. A 2012 ICTUS trial studied citicoline for acute ischemic stroke (2,298 patients), finding safety but no significant efficacy advantage for that specific indication. For healthy individuals, a 2015 study showed improved attention and psychomotor speed with 250 mg/day citicoline.

CDP-Choline (Citicoline) vs Piracetam: How They Compare

Like Alpha-GPC, CDP-Choline is a complement to piracetam rather than a replacement. Both provide choline for acetylcholine synthesis, preventing the headaches associated with piracetam use. CDP-Choline offers the additional benefit of cytidine/uridine for membrane repair, while Alpha-GPC delivers more choline per gram. Either is an excellent pairing with piracetam. Elite Bio Supply carries piracetam (1200 mg, 100 tablets) for researchers building comprehensive nootropic protocols.

Legal Status in Canada

CDP-Choline is classified as a dietary supplement in Canada and the United States. It is a prescription drug in some European countries (e.g., as Ceraxon in Spain).

Related Resources

• Piracetam Dosage Guide
• Piracetam Side Effects
• Buy Piracetam in Canada
• The Complete Guide to Racetam Nootropics

What Is Alpha-GPC?

Alpha-GPC (alpha-glycerophosphocholine) is a natural choline compound found in the brain and a highly bioavailable source of choline supplementation. It is approximately 40% choline by weight and crosses the blood-brain barrier efficiently, making it the preferred choline source for nootropic stacking with racetams like piracetam.

How Alpha-GPC Works

Alpha-GPC is hydrolyzed in the gut to glycerophosphate and free choline. The choline crosses the blood-brain barrier and serves as a precursor for acetylcholine synthesis. This is particularly relevant when stacking with racetams, which increase acetylcholine utilization. Alpha-GPC also supports phosphatidylcholine synthesis in neuronal membranes, contributing to membrane structural integrity. Additionally, Alpha-GPC has been shown to stimulate growth hormone release in some studies.

Alpha-GPC Dosage

Standard dose: 300 to 600 mg per day. When pairing with piracetam, 300 mg Alpha-GPC per 1,200 mg piracetam is a commonly used ratio. Clinical trials for cognitive decline have used 400 mg three times daily (1,200 mg/day total). Take with or without food.

Clinical Evidence

A 2003 meta-analysis in Clinical Therapeutics reviewed 13 published clinical trials of Alpha-GPC totaling 4,054 patients. The analysis found consistent improvements in cognitive measures across studies in patients with dementia and cerebrovascular disease. A 2015 study in the Journal of the International Society of Sports Nutrition found that Alpha-GPC supplementation increased power output in athletes. Alpha-GPC is approved as a prescription drug in some European countries (e.g., Italy, as Delecit).

Alpha-GPC vs Piracetam: How They Compare

Alpha-GPC is not an alternative to piracetam but rather an ideal complement. The two compounds work synergistically: piracetam increases acetylcholine utilization in the brain, while Alpha-GPC supplies the choline needed to meet that increased demand. Stacking Alpha-GPC with piracetam prevents the headaches commonly associated with piracetam use and may enhance the cognitive benefits of both compounds. Elite Bio Supply carries piracetam (1200 mg, 100 tablets) for researchers building nootropic stacks.

Legal Status in Canada

Alpha-GPC is classified as a dietary supplement in Canada and the United States. It is freely available without prescription.

Related Resources

• Piracetam Dosage Guide
• Piracetam Side Effects
• Buy Piracetam in Canada
• The Complete Guide to Racetam Nootropics

What Is Noopept?

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic peptide-derived nootropic developed in Russia in 1996. It is often grouped with racetams due to similar cognitive effects, but it has a distinct chemical structure. Noopept is estimated to be 1,000 times more potent than piracetam by weight, though this reflects dosing differences (10-30 mg vs 2,400-4,800 mg) rather than a 1,000x stronger effect.

How Noopept Works

Noopept is metabolized into cycloprolylglycine, which modulates AMPA and NMDA receptors. It increases NGF (nerve growth factor) and BDNF (brain-derived neurotrophic factor) expression in the hippocampus, which supports neuroplasticity and long-term memory formation. Noopept also has demonstrated neuroprotective properties against oxidative stress and amyloid toxicity in preclinical studies.

Noopept Dosage

Standard research dose: 10 to 30 mg per day, taken sublingually or orally. The extremely low dose compared to racetams is due to high bioavailability and potent receptor affinity. Half-life is approximately 30 to 60 minutes, but the downstream effects on NGF/BDNF persist longer.

Clinical Evidence

Most clinical data comes from Russian studies. A 2009 study in the Bulletin of Experimental Biology and Medicine showed Noopept improved cognitive function in patients with mild cognitive impairment. A 2014 study demonstrated neuroprotective effects against amyloid-beta toxicity. Western peer-reviewed data is limited, and Noopept is not recognized by the FDA, Health Canada, or EMA. The compound is primarily available for research purposes.

Noopept vs Piracetam: How They Compare

Noopept and piracetam target overlapping but distinct pathways. Piracetam has over 50 years of clinical research, a Cochrane review of 24 trials, and well-characterized safety data. Noopept has a much smaller evidence base, primarily from Russian studies with limited Western replication. Piracetam’s advantage is the depth and quality of its clinical evidence. Noopept’s advantage is its low effective dose and neurotrophic factor upregulation. For researchers prioritizing evidence-backed compounds, piracetam remains the gold standard racetam.

Legal Status in Canada

Noopept is not a controlled substance in Canada or the United States. It is not scheduled and is available for research purposes.

Related Resources

• Piracetam Dosage Guide
• Piracetam Side Effects
• Buy Piracetam in Canada
• The Complete Guide to Racetam Nootropics

What Is Aniracetam?

Aniracetam is a fat-soluble racetam nootropic developed by Hoffmann-La Roche in the 1970s. It is approximately 5 to 10 times more potent than piracetam by weight and has a shorter half-life (1 to 2.5 hours). Aniracetam is prescribed in Japan and some European countries for cognitive impairment, while it remains unscheduled in Canada and the United States.

How Aniracetam Works

Aniracetam modulates AMPA receptors (like piracetam) but also affects metabotropic glutamate receptors and has documented anxiolytic properties. It increases acetylcholine release in the prefrontal cortex and hippocampus. Unlike piracetam, aniracetam also modulates dopamine and serotonin transmission, which may explain its reported effects on mood and anxiety reduction. Its fat-solubility means it should be taken with a fat-containing meal for optimal absorption.

Aniracetam Dosage

Standard research dose: 750 to 1,500 mg per day, divided into 2 to 3 doses due to the short 1 to 2.5 hour half-life. Must be taken with food (fat-soluble). Choline co-supplementation is recommended, as with all racetams.

Clinical Evidence

A 1993 study in Psychopharmacology found that aniracetam improved cognitive performance in elderly subjects with mild cognitive impairment. A 2001 study in the European Journal of Pharmacology demonstrated anxiolytic effects in animal models through modulation of dopamine and serotonin. However, large-scale human RCTs are limited. Most clinical data comes from Japan, where aniracetam (Draganon) has been prescribed since the 1990s.

Aniracetam vs Piracetam: How They Compare

Aniracetam and piracetam are both racetams that modulate AMPA receptors and enhance cholinergic function. Piracetam is water-soluble, has a longer half-life (5 hours vs 1-2.5 hours), requires fewer daily doses, and has a much larger body of clinical trial data (60+ trials, Cochrane review). Aniracetam offers additional anxiolytic properties but requires more frequent dosing and must be taken with food. For researchers seeking a well-studied racetam with the broadest evidence base, piracetam is the standard choice.

Legal Status in Canada

Aniracetam is not a controlled substance in Canada. It is not scheduled under the CDSA and is available for research purposes.

Related Resources

• Piracetam Dosage Guide
• Piracetam Side Effects
• Buy Piracetam in Canada
• The Complete Guide to Racetam Nootropics

Can Enclomiphene Treat Low Testosterone?

Enclomiphene can raise testosterone to normal levels in men with secondary hypogonadism, also called central or hypogonadotropic hypogonadism. In this condition, the testes are capable of producing testosterone but are not receiving adequate stimulation from LH. LH is produced by the pituitary in response to GnRH pulses from the hypothalamus. When hypothalamic GnRH output is insufficient, or pituitary LH response is blunted, testosterone production falls below normal even though the testes themselves are healthy.

Enclomiphene addresses this problem at its source. By blocking estrogen receptors at the hypothalamus and pituitary, it removes the inhibitory estrogen feedback signal that was suppressing GnRH and LH. GnRH pulse frequency increases, LH rises, and LH stimulates Leydig cells in the testes to increase testosterone production. The result is higher endogenous testosterone, achieved without introducing exogenous androgens and without suppressing the HPG axis.

The key word is secondary. Enclomiphene does not work for primary hypogonadism, where the testes themselves are the problem. In primary hypogonadism (also called hypergonadotropic hypogonadism), LH is already elevated because the pituitary is trying to stimulate non-responsive testes. Blocking estrogen feedback further would raise LH even higher without producing more testosterone, because the Leydig cells cannot respond. Enclomiphene would be ineffective and the correct approach for primary hypogonadism is testosterone replacement therapy.

Phase III Evidence for Enclomiphene in Low Testosterone

The Phase III clinical trial, Wiehle et al., 2014, doi:10.1111/andr.12150, enrolled men with morning testosterone below 300 ng/dL and low or inappropriately normal LH, which is the diagnostic profile of secondary hypogonadism. Men with LH above the normal range were excluded, as they would represent primary hypogonadism where enclomiphene would not be appropriate.

At 25 mg per day for 16 weeks, 77 percent of subjects achieved testosterone normalization (above 300 ng/dL), and many reached the mid-normal range of 400 to 600 ng/dL. The testosterone normalization rate was comparable to the topical testosterone gel arm (81 percent). The critical differentiator was that the enclomiphene group maintained or improved sperm concentration and gonadotropin levels, while the testosterone gel group experienced significant suppression of both. For the 77 percent of secondary hypogonadism subjects who respond to enclomiphene, the testosterone outcome is essentially equivalent to TRT but without the fertility and HPG axis suppression consequences.

How to Confirm Secondary Hypogonadism Before Researching Enclomiphene

The diagnostic pattern that confirms secondary hypogonadism is straightforward on a standard hormone panel. The research subject should show low morning total testosterone (typically below 300 ng/dL, though some define the threshold at 350 ng/dL), combined with LH that is low or inappropriately in the normal range. “Inappropriately normal” means that if testosterone is severely low, the pituitary should be responding with high LH. If LH is normal or low in the presence of low testosterone, the hypothalamic-pituitary signaling is insufficient, confirming the central origin of the deficiency.

If LH is clearly elevated (above the normal range) in the presence of low testosterone, this is primary hypogonadism: the pituitary is already trying to compensate but the testes cannot respond. Enclomiphene would not be appropriate in this scenario.

Additional tests worth running at baseline include FSH (to assess spermatogenesis signaling), estradiol (to understand the estrogenic environment), and prolactin (elevated prolactin can suppress GnRH and is a treatable cause of secondary hypogonadism that should be identified before starting SERM protocols).

Dosing for Low Testosterone Research

Research protocols for secondary hypogonadism typically start at 12.5 mg per day for the first 4 weeks. This conservative starting dose allows assessment of response before escalating. At 4 weeks, if testosterone has risen meaningfully but not yet normalized, escalating to 25 mg per day is the standard step. If response is robust at 12.5 mg, the lower dose may be maintained to minimize estradiol rise.

The 25 mg dose was the primary efficacious dose in Phase III. Men with more severe baseline deficits (testosterone below 200 ng/dL) more commonly required 25 mg to achieve normalization. Men with borderline low testosterone (200 to 280 ng/dL) often responded adequately at 12.5 mg.

Dosage Note

Elite Bio Supply’s 50 mg tablets in 5-count packs allow both 12.5 mg (quarter tablet) and 25 mg (half tablet) dose tiers. A pill cutter produces cleaner splits than breaking by hand. At 12.5 mg per day, one 5-tablet pack covers 20 days. At 25 mg per day, one pack covers 10 days.

Frequently Asked Questions

How do I know if I have primary or secondary hypogonadism?

The distinction is made by measuring LH alongside testosterone. A morning hormone panel including total testosterone, free testosterone, LH, and FSH provides the necessary information. If both LH and testosterone are low (or LH is normal when testosterone is clearly low), that is consistent with secondary hypogonadism. If LH is high and testosterone is low, that is consistent with primary hypogonadism. This test should be run on at least two separate mornings before drawing conclusions, as single-point hormone measurements have high variability.

What if enclomiphene raises testosterone but I still feel low?

Normalization of serum testosterone does not guarantee symptomatic resolution of all low-testosterone symptoms. Several factors can contribute to persistent symptoms despite improved testosterone. Estradiol may have risen disproportionately relative to testosterone, which can cause mood disruption, water retention, and libido effects. Testosterone may be converting to dihydrotestosterone (DHT) at atypical rates. Sleep quality, stress, thyroid function, and other systemic factors contribute to the same symptoms. A repeat hormone panel including estradiol alongside testosterone is the first step in understanding incomplete symptomatic response.

How long does a low testosterone research protocol with enclomiphene typically run?

Phase III evaluated 16 weeks as the primary endpoint. Many research designs use 12 weeks as the standard duration for secondary hypogonadism normalization protocols. Some researchers extend to 6 months to assess whether the response is maintained over time. Bloodwork at baseline, 4 weeks, and 12 weeks provides the minimum monitoring framework for a standard protocol. Decisions about whether to continue, adjust dose, or conclude the protocol are based on testosterone response and symptom changes tracked at these intervals.

Sourcing Enclomiphene in Canada

Elite Bio Supply stocks enclomiphene citrate with third-party COA documentation. Domestic Canadian shipping via Canada Post. For researchers designing multi-week low testosterone protocols, we recommend ordering sufficient quantity for the full planned protocol duration to avoid supply interruptions.

Related Guides

• Enclomiphene for Secondary Hypogonadism
• Enclomiphene Dosage Guide
• Enclomiphene vs TRT: Full Comparison
• Buy Enclomiphene in Canada

Where Can You Buy Enclomiphene in Canada?

Enclomiphene occupies a clear position in the Canadian market: it is available from research compound suppliers, not from pharmacies or retail supplement stores. Understanding where it sits and why is useful before deciding where to purchase.

Pharmacies in Canada dispense drugs that hold a Health Canada Drug Identification Number (DIN) and are prescribed by a licensed physician. Enclomiphene does not have a DIN in Canada. It is not an approved pharmaceutical product in this country. No Canadian pharmacy will stock it, and no physician can write a legal prescription for it as an approved drug, because no such approval exists. If you have seen offers to obtain “prescription enclomiphene” in Canada, those products do not exist in a legitimate pharmacy channel.

Amazon, general supplement retailers, and most e-commerce platforms do not carry research compounds like enclomiphene. These platforms either actively prohibit unapproved research compounds in their seller agreements, or their suppliers are not equipped to verify and certify the purity of compounds at the standard required for research use.

What Defines a Quality Research Compound Supplier

Not all research compound suppliers operate at the same standard. When evaluating suppliers for enclomiphene specifically, the following criteria separate reliable sources from unreliable ones.

Third-party certificate of analysis (COA): Every batch should be tested by an independent laboratory for identity (confirming the compound is actually enclomiphene, not a substitute or mislabeled product), purity (percent of the batch that is enclomiphene, with impurity identification), and concentration (confirming the stated dose matches actual content). Without a third-party COA, you cannot verify that what you are ordering is what is in the package. First-party COAs from the same company that made the product are not independent verification.

Domestic Canadian shipping: International shipments entering Canada are subject to CBSA review. Although enclomiphene is not a controlled substance, customs delays and package inspections are variable and unpredictable. Domestic suppliers ship within Canada via Canada Post or private couriers, which eliminates customs entirely. For consistency, predictability, and privacy, domestic Canadian suppliers are strongly preferable.

Proper labeling: Research compounds should be accurately labeled with compound name, concentration, quantity, and a research compound disclaimer. Unlabeled or mislabeled products are a quality signal failure regardless of the claimed content.

Established reputation: Supplier reputation in the research community is built over years of consistent, accurate, high-quality product. New suppliers with no track record, or suppliers that are impossible to verify, carry higher product quality risk than established operations.

Elite Bio Supply: What We Offer

Elite Bio Supply is a Canadian domestic research compound supplier. Our enclomiphene citrate is pharmaceutical grade, manufactured to the same chemical specification as the compound used in Phase II and Phase III clinical trials of Androxal. Every batch is third-party tested by an independent laboratory, and certificates of analysis are available for review.

Our product comes in 50 mg tablets in 5-count packs. This format is convenient for the 12.5 to 25 mg per day doses used in standard research protocols, as tablets are easily split. We ship via Canada Post across Canada, with no customs exposure. Shipping typically takes 3 to 7 business days to addresses across the country.

We accept cryptocurrency payment, which many research compound purchasers prefer for privacy. Payment options and current pricing are listed on the product page.

Comparing Purchase Options

Dosage Note

Research protocols for secondary hypogonadism and PCT use 12.5 to 25 mg per day. The 50 mg tablet format from Elite Bio Supply requires splitting: half tablet for 25 mg, quarter tablet for 12.5 mg. A pill cutter is recommended for clean, even splits. For multi-week research designs, ordering 4 to 5 packs at once is typical for 4-week increments at 25 mg per day.

Frequently Asked Questions

Can I get enclomiphene through a Canadian compound pharmacy?

Compound pharmacies in Canada prepare custom formulations from bulk pharmaceutical ingredients, typically for patients with documented medical need that cannot be met by a commercially available product. Some compound pharmacies have prepared clomiphene formulations off-label. Whether a compound pharmacy could prepare enclomiphene specifically depends on their formulary, the availability of enclomiphene ingredient in their supply chain, and whether a prescribing physician will write an off-label compounding order. This is a more complex and expensive pathway than purchasing from a research compound supplier, and most researchers do not pursue it.

How do I verify the COA for a research compound I purchased?

A legitimate COA from a third-party laboratory will include the name of the testing laboratory, the date of testing, the batch number tested, the specific tests performed (identity, purity, concentration), the results for each test, and the pass/fail determination. The laboratory should be identifiable and ideally ISO/IEC 17025 accredited. If a supplier cannot provide a COA or provides one that lacks an identifiable testing laboratory, treat that as a significant red flag.

How much enclomiphene do I need for a complete research protocol?

At 25 mg per day: a 4-week protocol requires approximately 700 mg total, or 14 tablets, which is slightly under 3 packs. An 8-week protocol requires approximately 28 tablets (5 to 6 packs). A 12-week protocol requires approximately 42 tablets (8 to 9 packs). At 12.5 mg per day, roughly half these quantities apply. Planning total quantity before ordering avoids mid-protocol supply interruptions.

Sourcing Enclomiphene in Canada

Elite Bio Supply is the domestic Canadian source for enclomiphene citrate. Third-party tested, properly labeled, Canada Post shipping, cryptocurrency accepted. View our current stock and pricing on the product page below.

Related Guides

• Is Enclomiphene Legal in Canada?
• Enclomiphene Dosage Guide
• Enclomiphene for Secondary Hypogonadism
• Buy Enclomiphene in Canada